Gilead exercises option, triggering $10M payment to MacroGenics
What's the deal? MacroGenics (NASDAQ: MGNX) said Gilead SciencesDealroom has a profile for this one. Try Dealroom → has exercised its option to obtain an exclusive license to a preclinical bispecific program, triggering a $10 million payment. The licensed solid-tumor program uses MacroGenics' TRIDENT platform and targets two undisclosed antigens.
What's the endgame? The deal stems from a 2022 collaboration covering three programs: MGD024, a clinical-stage CD123 × CD3 DART molecule, plus two preclinical bispecific programs. MacroGenics remains eligible for up to roughly $1.6 billion in future development, regulatory, and commercial milestones, plus royalties on any worldwide net sales.
Why it matters? The $10 million is an incoming payment set against MacroGenics' cash and equivalents of $66.5 million as of March 31, 2026. It also validates progress under the Gilead partnership as a program advances from option to license.
What could go wrong? The licensed targets remain undisclosed and the bulk of the $1.6 billion is contingent on hitting future milestones. Preclinical programs carry long, uncertain development timelines.
The signal: The news lands amid broader biotech strength, with peers ATOSDealroom has a profile for this one. Try Dealroom → up 4.87% and IFRXDealroom has a profile for this one. Try Dealroom → up 5.38% in the 2026 snapshot. For MacroGenics, milestone-driven cash from partners like Gilead offers non-dilutive funding while its own pipeline advances.
Read more: Stock Titan
Image credit: foteih
